Eli Lilly pays $10m
Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244%
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. | Eli Lilly has acquired Organovo’s lead asset,
M&A News: Eli Lilly (LLY) Expands IBD Pipeline with Organovo’s FXR Program
The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid X receptor (FXR) agonists,
1don MSN
Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...
Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314.
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...
Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a ...
Eli Lilly said it plans to build three new plants in the U.S. to make the key ingredients used in pharmaceuticals, part of a ...
Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...
(Reuters) - Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback